Table 3. Treatment details and clinical course.
| Variables | No. (%) or median (IQR) |
|---|---|
| Treatment | |
| Antitussives, expectorants, antibiotics | 5 (12.5) |
| Antitussives, expectorants only | 3 (7.5) |
| Haemostatics | 1 (2.5) |
| Laser | 2 (5.0) |
| Follow-up period for all patients (months) | 13.5 (5.5–56.1) |
| Aggravation of symptoms | |
| Sputum | 2 (5.0) |
| Dyspnoea | 1 (2.5) |
| Chest discomfort | 1 (2.5) |
| Follow-up for more than 36 months | 15 (37.5) |
| Sputum | 2 (5.0) |
| Chest discomfort | 1 (2.5) |
| Mortality | |
| Unknown | 7 (17.5) |
| Brain metastasis | 1 (2.5) |
| Pneumothorax | 1 (2.5) |
IQR, interquartile range.